Cell & Gene Therapies: A Regulatory Update

Return to Insights Center

Related Insights

Blog

CAR-T product development: an assessment of FDA’s final guidance for industry

Feb 27, 2024

Podcast

Rare endpoints: Delivering on unmet patient needs

May 7, 2024

Report

New Medicines, Novel Insights: Accelerating development of cell and gene therapies

May 22, 2023

Podcast

CAR-T boxed warnings: What comes next?

Mar 6, 2024

Blog

Studying multiple versions of a cellular or gene therapy product in an early-phase clinical trial

Nov 19, 2021

Blog

CAR-T boxed warnings: regulatory precedents and opportunities

Feb 9, 2024

Blog

Making cell and gene therapy more accessible in the treatment of solid tumors

Jun 4, 2024

Article

Three ways to improve your chances that insurers will pay for a new CGT

Feb 18, 2021

Playbook

Mitigating risk, protecting potential: Practical strategies that position cell and gene therapy development for success

Mar 28, 2023

Webinar

How to navigate China’s regulatory environment

Feb 15, 2023

Blog

Preparing for the New Era of Hybrid Regulatory Inspections

Jul 11, 2022

Article

New FDA Guidance Addresses the Need for Data-Generation Strategies Across the Drug Development Lifecycle

May 10, 2022